SCHEMBL959660

SCHEMBL959660

C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CCC(CC(=O)O)(c2ccccc2)OC1=O

nearest known ligand 0.79

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 20/20 0.79
CYP3A4 P08684 13/20 0.76
CYP2C9 P11712 7/20 0.76
CYP2C19 P33261 6/20 0.76
HSD3B2 P26439 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855231 1.00 HSD11B1 (0.79) HSD11B1CYP3A4CYP2C9CYP2C19HSD3B2
SCHEMBL959659 1.00 HSD11B1 (0.79) HSD11B1CYP3A4CYP2C9CYP2C19HSD3B2
SCHEMBL959571 0.91 HSD11B1 (0.73) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL1847308 0.91 HSD11B1 (0.73) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL959570 0.91 HSD11B1 (0.73) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL955608 0.90 HSD11B1 (0.86) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL955610 0.90 HSD11B1 (0.86) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL955606 0.90 HSD11B1 (0.86) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL13625238 0.89 HSD11B1 (0.74) HSD11B1CYP3A4CYP2C9CYP2C19
SCHEMBL590318 0.88 HSD11B1 (0.79) HSD11B1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183228-B1 CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 VITAE PHARMACEUTICALS INC (US) 2014-08-20 EP disclosed
US-8575156-B2 Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8487094-B2 Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-16 US disclosed
US-8329897-B2 Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2012-12-11 US disclosed
EP-2183229-B1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS INC (US) 2012-04-18 EP disclosed
US-20110269957-A1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals ,Inc. 2011-01-20 US disclosed
US-20100256363-A1 SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. 2010-10-07 US disclosed
EP-2183228-A1 CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 Vitae Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009017664-A1 CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269957-A1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885CYP3A4 390/4885CYP2C9 528/4885
US-20100256363-A1 SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885CYP3A4 526/4885CYP2C9 721/4885
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885CYP3A4 272/4885CYP2C9 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.